EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma

Adena Pepich, Conny Tümmler, Sara Abu Ajamieh, Diana Treis, Ammelie Svea Boje, Quinty Vellema, Ioanna Tsea, Emma Åkerlund, Brinton Seashore-Ludlow, Shahrzad Shirazi Fard, Per Kogner, John Inge Johnsen und 1 weitere

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Adena Pepich und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Sweden. Electronic address: adena.pep…. Hauptthemen laut MEDLINE: rho-Associated Kinases, Neuroblastoma, Drug Synergism, Zebrafish. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Cancer Research Foundations of Radiumhemmet, Karolinska Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-risk neuroblastoma has a poor prognosis despite intensive treatment, highlighting the need for new therapeutic strategies. Genetic alterations in activators and inactivators of Rho GTPase have been identified in neuroblastoma suggested to activate Rho/Rho-kinase (ROCK) signaling. ROCK has also been implicated in therapy resistance. Therefore, we have explored the efficacy of the dual ROCK inhibitor RKI-1447 in neuroblastoma, emphasizing combination strategies. Treatment with RKI-1447 resulted in decreased growth, increased cell death, and inhibition of N-MYC in vitro and in vivo. A combination screen revealed enhanced effects between RKI-1447 and BET inhibitors. Synergistic effects from RKI-1447 and the BET inhibitor, ABBV-075, were confirmed in various neuroblastoma models, including zebrafish. Interestingly, ABBV-075 increased phosphorylation of both myosin light chain 2 and cofilin, downstream effectors of ROCK, increases that were blocked by adding RKI-1447. The combination treatment also augmented an inhibitory effect on C-MYC and, less pronounced, N-MYC protein expression. BET inhibitors have shown preclinical efficacy against neuroblastoma, but acquired resistance has limited their therapeutic benefit. We reveal that the combination of ROCK and BET inhibitors offers a promising treatment approach that can potentially mitigate resistance to BET inhibitors and reduce toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesNeuroblastomaDrug SynergismZebrafishHumansAnimalsCell Line, TumorXenograft Model Antitumor AssaysN-Myc Proto-Oncogene ProteinCell ProliferationProtein Kinase InhibitorsMyosin Light ChainsPhosphorylationSignal TransductionActin Depolymerizing FactorsMiceAntineoplastic Combined Chemotherapy ProtocolsCell DeathApoptosisProto-Oncogene Proteins c-mycBromodomain Containing ProteinsProteinsCardiac Myosins

Stichwörter der Autor:innen

BET inhibitorDrug combinationsNeuroblastomaRKI-1447ROCK inhibitor

Substanzen

rho-Associated KinasesROCK2 protein, humanROCK1 protein, humanN-Myc Proto-Oncogene ProteinProtein Kinase Inhibitorsmyosin light chain 2Myosin Light ChainsMYCN protein, humanbromodomain and extra-terminal domain protein, humanActin Depolymerizing Factors

Autor:innen und Institutionen

  • Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Sweden. Electronic address: adena.pepich@ki.se.
  • Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Sweden.
  • Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Sweden; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Christian Albrechts U…
  • Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
  • Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Sweden. Electronic address: malin.wickstrom@ki.se.

Förderung

  • Swedish Cancer Society
  • Cancer Research Foundations of Radiumhemmet
  • Karolinska Institute
  • Anna Brita and Bo Castegren Memorial Foundation
  • Childhood Cancer Foundation

Zitieren

APA

Pepich, A., Tümmler, C., Abu Ajamieh, S., Treis, D., Boje, A. S., Vellema, Q., Tsea, I., Åkerlund, E., Seashore-Ludlow, B., Shirazi Fard, S., Kogner, P., Johnsen, J. I., & Wickström, M. (2024). The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217261

Vancouver

Pepich A, Tümmler C, Abu Ajamieh S, Treis D, Boje AS, Vellema Q, et al. The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217261

BibTeX
@article{Pepich2024,
  author = {Pepich, Adena and Tümmler, Conny and Abu Ajamieh, Sara and Treis, Diana and Boje, Ammelie Svea and Vellema, Quinty and Tsea, Ioanna and Åkerlund, Emma and Seashore-Ludlow, Brinton and Shirazi Fard, Shahrzad and Kogner, Per and Johnsen, John Inge and Wickström, Malin},
  title = {The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217261}
}
Kostenlos starten →